Active LIFUP Treatment
Device8 LIFUP Treatments
Other names: BX Pulsar 1002
NCT Number: NCT04557891
There are few treatment options available for patients once they have failed standard psychopharmacological therapy for generalized anxiety disorder. Existing brain stimulation methods such as rTMS fail to target deep brain structures associated with anxiety disorders; structures such as the amygdala. In this double-blind sham-controlled clinical trial, the investigators propose to establish baseline severity of anxiety in 48 patients, then deliver eight treatments over four sessions of focused ultrasound stimulation to the amygdala. Anxiety severity will be assessed using standard psychometric scales after each session, and at follow-ups.
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Not applicable
University of California, Los Angeles, Los Angeles, California, United States
Anxiety disorders have tremendous disease burden in the United States. Up to 1 in 3 Americans will be diagnosed with an anxiety disorder in their lifetimes. Anxiety treatment is typically consisting of psychotherapy (e.g. cognitive behavioral therapy) and medication management (e.g. benzodiazepines, selective serotonin reuptake inhibitors, etc). With major depressive disorder, rTMS is a suitable alternative treatment for refractory depression, rTMS is not approved for treatment of anxiety, nor can rTMS stimulate deep enough to reach those brain circuits involved in anxiety (e.g. the amygdala). Focused ultrasound is a new treatment modality being developed for several different neuropsychiatric conditions. In this study, the investigators propose to randomize 48 individuals to either active or sham treatment. Each participant will be evaluated to establish a baseline diagnose of generalized anxiety disorder, and then will be reassessed after each treatment session (of which there are four). One week and one month after the last treatment session, the investigators will conduct follow-up evaluations.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
8 LIFUP Treatments
Other names: BX Pulsar 1002
8 sham LIFUP treatments
Time frame: 1 week after the fourth LIFUP treatment
HAM-A is a rating scale for measuring the severity of anxiety symptoms.
Contact information is provided by the study sponsor or research team.
Andrew Bishay, BS
CONTACT
Margaret G Distler, MD,PhD
CONTACT
University of California, Los Angeles
Other
Feasibility of Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06376734
Anxiety Disorders, Behavior
Sunnyvale, California, United States
View Trial DetailsNCT07489651
Anxiety Disorders, Generalized Anxiety Disorder
Gilbert, Arizona, United States
View Trial DetailsNCT07478744
Anxiety Disorders, Generalized Anxiety Disorder
London, United Kingdom
View Trial DetailsNCT05467683
Anxiety Disorders, Generalized Anxiety Disorder
Boston, Massachusetts, United States
View Trial Details